体重变化：探究在 CF 成年患者中起始使用 elexacaftor/tezacaftor/ivacaftor 对体重和身体成分的影响。
Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor/tezacaftor/ivacaftor in adults with CF.
机构信息
All Wales Adult Cystic Fibrosis Centre, Wales, UK.
All Wales Adult Cystic Fibrosis Centre, Wales, UK.
出版信息
J Cyst Fibros. 2023 Sep;22(5):847-850. doi: 10.1016/j.jcf.2023.06.002. Epub 2023 Jun 23.
BACKGROUND
Life expectancy for people with CF (PwCF) continues to increase. However, a trend of overweight and obesity is emerging along with concern of developing comorbitities. Body composition (BC) is associated with several health indices. However, body mass index (BMI) does not provide information on BC.
METHODS
BMI, fat mass (FM), fat free mass (FFM), using bioelectrical impedance, lung function and sweat chloride (SwCl) were assessed in adult PwCF in routine clinic before and after commencement of the CFTR modulator Elexacaftor/Tezacaftor/Ivacaftor.
RESULTS
109 PwCF (76 male) underwent assessments at both time points. In all PwCF a significant upward trend in BMI was observed (p < 0.001). Males significantly gained more FFM compared to females (p0.03), whilst prevalence of normal weight obesity increased primarily in females (25-38%).
CONCLUSION
Routine BC assessment identifies individuals with elevated FM or depleted FFM enabling individualised care with the focus of optimising BC.
背景
囊性纤维化（CF）患者的预期寿命持续延长。然而，超重和肥胖的趋势也随之出现，同时人们也开始担心会出现合并症。身体成分（BC）与许多健康指标相关。然而，体重指数（BMI）并不能提供 BC 的信息。
方法
在开始使用 CFTR 调节剂 Elexacaftor/Tezacaftor/Ivacaftor 之前和之后，在常规临床中评估了成年 CF 患者的 BMI、脂肪量（FM）、去脂体重（FFM），使用生物电阻抗法、肺功能和汗液氯化物（SwCl）。
结果
109 名 CF 患者（76 名男性）在两个时间点都接受了评估。所有 CF 患者的 BMI 均呈显著上升趋势（p<0.001）。与女性相比，男性的 FFM 显著增加（p<0.03），而正常体重肥胖的患病率主要在女性中增加（25-38%）。
结论
常规 BC 评估可识别出 FM 升高或 FFM 减少的个体，从而能够进行个性化护理，重点是优化 BC。
Zotero 插件